← Back to Search

Monoclonal Antibodies

REGN1908-1909 for Allergic Eye

Phase 3
Recruiting
Research Sponsored by Regeneron Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and day 113
Awards & highlights
Pivotal Trial

Summary

This trial is testing two experimental drugs, REGN1908 and REGN1909, combined as REGN1908-1909, to see if they can reduce eye allergy symptoms from cat allergies

Who is the study for?
Adults with a history of moderate to severe cat allergy for at least 2 years, confirmed by skin and blood tests. Participants must have significant eye allergy symptoms when near cats, not live with cats for the past 3 years, and avoid contact with cats during the trial.
What is being tested?
The study is testing REGN1908-1909, a combination of two experimental drugs aimed at reducing allergic eye reactions in adults with cat allergies. It's being compared to a placebo to evaluate safety and effectiveness.
What are the potential side effects?
Potential side effects may include typical drug reaction symptoms such as irritation at the injection site, headache, fatigue or more serious immune responses like developing antibodies against the study drug.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and day 113
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and day 113 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Ocular itch score
Secondary study objectives
Change in cat tSPT
Ciliary redness score
Conjunctival redness score
+6 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: REGN1908-1909Experimental Treatment2 Interventions
Group II: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Regeneron PharmaceuticalsLead Sponsor
671 Previous Clinical Trials
385,754 Total Patients Enrolled
Clinical Trial ManagementStudy DirectorRegeneron Pharmaceuticals
284 Previous Clinical Trials
254,847 Total Patients Enrolled
~47 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top